3E Bioventures’ Post

EpimAb Biotherapeutics, Inc. and Vignette Bio, Inc. announced today that EpimAb and Vignette have entered into a license agreement for EpimAb’s BCMA-targeting T-cell engager (TCE) EMB-06. Under this agreement, EpimAb will grant Vignette the exclusive rights to develop and commercialize EMB-06 outside of Greater China, while EpimAb shall retain the rights to EMB-06 in Greater China. EpimAb will receive total upfront considerations of $60 million in cash and equity of Vignette, and will be eligible to receive up to $575 million development, regulatory and commercial milestones, plus royalties on net sales. For more information please visit: https://lnkd.in/g3DkQEz8

Avirmax CMC Inc. Successfully Delivers GMP Lots of AAV Vector Products for Client's Phase I/IIa Clinical Trial in the US. The GMP AAV product lots were produced, tested and packaged at Avirmax CMC's cutting-edge facility in the City of Hayward, the heart of San Francisco Bay Area, which is equipped with single use technologies for scalable and robust manufacturing processes. "Our team at Avirmax CMC is thrilled to have reached this pivotal point in our journey. Delivering to our first customer with GMP lot of AAV vector product underscores our commitment to excellence and our capability to meet stringent regulatory standards and customer's satisfaction," said Shengjiang Liu, CEO & CSO of Avirmax CMC Inc. https://lnkd.in/g_mafr2x #GeneTherapy #CMC #ClinicalTrial #AAV

We have some very exciting news to announce today! Our AI-powered synthetic imaging software, SubtleSYNTH™, has received FDA clearance and is now available for clinical use in the US! 🚀 SubtleSYNTH™ uses deep learning to generate synthetic STIR images from already-acquired T1 and T2 weighted contrasts, creating STIR images with zero acquisition time that are interchangeable with conventionally acquired STIR images. This is an industry first, and we thank all of the members on the @SubtleMedical team and the clinical partners who helped us reach this milestone. This is just the start, as we explore plans to expand to Brain and MSK imaging next. Read the full press release below, and be sure to join us at RSNA this year to learn more about how SubtleSYNTH™ and our suite of imaging solutions can redefine your MRI imaging program. https://lnkd.in/g6Hr7uGC #AI #HealthcareInnovation #MedicalImaging #FDAcleared #SubtleSYNTH #SubtleMedical #MRI #Radiology #RSNA2023 #HealthcareTransformation

Rapafusyn is excited to announce the initial closings of our A financing round with high-quality investors including 3E Bioventures, Proxima Ventures, and Lapam Capital. Together, we look forward to advancing our non-degrading molecular glue platform and accelerating our effort to discover and develop transformational drug therapeutics for the high unmet medical needs of patients. https://lnkd.in/etJV9Tjk

Biosion Today Presented Key Phase 2 POC Clinical Study Results for Bosakitug, an Anti-TSLP mAb, in Atopic Dermatitis Subjects at the Revolutionizing Atopic Dermatitis Conference. We are excited to see that Bosakitug's efficacy will lead to new therapeutic options for patients! #antibody #TSLP #AtopicDermatitis

We are thrilled to come to San Diego for BIO 2024, to present Avirmax Biopharma’s reception of regulatory approval of its first investigational new drug (IND) using AAV.N54 product for wet age-related macular degeneration including PCV in multicenter, open labeled dose escalation study in the U.S. We also pleased to share Avirmax CMC’s completion of manufacturing, characterization and stability program qualification/ validation to achieve high quality and quantity AAV vectorized product for clinical use. BIO is the largest global organization in biotechnology industry. It holds its annual confetence conference in San Diego and Boston every other year alternatively. Avirmax Inc. is a member company BIO. Please come to our booth#1618.

Avirmax Biopharma Receives IND Approval to Initiate Phase I/IIa Trial for Wet AMD Including PCV. This significant milestone enables Avirmax Biopharma to commence clinical trials aimed at evaluating the safety, tolerability, and preliminary efficacy of its engineered adeno-associated virus (AAV) vector-mediated gene therapy in patients suffering from these debilitating ocular conditions. "We are thrilled to have received IND approval to advance our genetic medicine program into clinical trials," said Shengjiang Liu, CEO of Avirmax Biopharma. https://lnkd.in/gS3i5p52

Today Biosion presented key additional preclinical data for anti-SIRPα antagonistic antibody BSI-082 at PEGS Boston. We look forward to BSI-082 providing new treatment options for patients with solid tumors. #Biosion #antibody #PEGS